Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Diagnostic services	$ 1,586,000	$ 1,244,000
Royalties	25,000	25,000
Total revenues	1,611,000	1,269,000
Operating expenses:
Cost of services	937,000	659,000
Research and development	183,000	450,000
Sales and marketing	641,000	873,000
General and administrative	1,373,000	1,574,000
Patent amortization and royalties	60,000	76,000
Total operating expenses	3,194,000	3,632,000
Operating loss	(1,583,000)	(2,363,000)
Other income (expense):
Interest income		1,000
Interest expense	(302,000)	(6,000)
Warrant derivative gain	1,837,000
Total other income (expense)	1,535,000	(5,000)
Net income (loss)	(48,000)	(2,368,000)
Net loss attributable to common stockholders	(711,000)	(2,368,000)
Basic and diluted net income (loss) per share (in Dollars per share)	$ (0.02)	$ (2.21)
Basic and diluted net loss per share attributable to common stockholders (in Dollars per share)	$ (0.31)	$ (2.21)
Basic and diluted weighted average common shares outstanding (in Shares)	2,314,786	1,070,384
Series A Convertible Preferred Stock [Member]
Other income (expense):
Deemed dividends from issuing convertible preferred stock	(417,000)
Deemed dividends from issuing convertible preferred stock (in Dollars per share)	$ (0.18)
Series B Convertible Preferred Stock [Member]
Other income (expense):
Deemed dividends from issuing convertible preferred stock	$ (246,000)
Deemed dividends from issuing convertible preferred stock (in Dollars per share)	$ (0.11)